Lilly, Incyte-allied Chinese drugmaker Innovent bags Roche as partner in deal that could yield billions
China’s biologic powerhouse Innovent has snagged another illustrious partner: Roche.
The company — which made its public debut on Hong Kong Stock Exchange in 2018 raising a whopping $421 million — is already collaborating with a host of key biopharma and academic groups such as Eli Lilly, Incyte and the MD Anderson Cancer Center. Now, Innovent has inked a deal with Roche that grants it access to the Swiss drugmaker’s bispecific antibody and CAR-T technology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
